EastGate is aimed at using drug delivery innovations in the development of improved new formulations and alternative dosage forms of existing biologically active molecules. E-drops has been successfully
Currently, the company is exploring two combination treatments for relapsed ovarian cancer. As part of this advancement, a Phase II trial of CRLX101 plus Avastin is enrolling patients,
As part of the deal, NeuroVive Asia will get an upfront payment, a conditional milestone payment and royalty on potential future sales in South Korea. The deal will
The acquired business will now be combined with Ergomed’s existing fast growing post-marketing business, PrimeVigilance. The acquisition of Sound Opinion is part of Ergomed’s strategy of strengthening its
Designed using Visterra’s proprietary technology, VIS513 is a humanized monoclonal antibody that is designed to bind and potently neutralize all four serotypes of dengue virus. Preclinical trials of
Unituxin, a monoclonal antibody, is intended for use in children who have responded to an induction treatment with chemotherapy, followed by myeloablative therapy and autologous stem-cell transplantation. Neuroblastoma
Tanner Pharma Group includes three complementary divisions Tanner Clinical Trial Sourcing (TannerCTS), Tanner Global Access Programs (TannerGAP) and Tanner Licensing, Acquisition and Commercialisation (TannerLAC). The new firm’s complementary
The single-dose study is the first stage of the Phase I trial, which the company is currently carrying out for the oral agent of a new molecular entity
Aptensio XR is an extended-release formulation of methylphenidate capsule with an onset of effect of one hour and 12-hour duration of effect with about 40% of the active
A total of 2,157 patients with AHF were enrolled in the trial from over 200 centers across the US, Europe, Canada and Latin America. The TRUE-AHF Phase III
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.